Successful perioperative management of a patient with idiopathic thrombocytopenic purpura undergoing emergent appendectomy: Report of a case  by Toyomasu, Yoshitaka et al.
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INTRODUCTION:  Idiopathic  thrombocytopenic  purpura  (ITP)  is  an  autoimmune  disease  characterized  by
a  low  platelet  count  and  normal  bone  marrow.  Patients  with ITP undergoing  surgery  are  thought  to have
increased  risk  for  postoperative  complications  because  of their  thrombocytopenia.
PRESENTATION OF  CASE:  we  report  the  case  of a 66-year-old  woman  with  ITP who  required  an  emergency
operation  for  acute  appendicitis  associated  with  disseminated  intravascular  coagulation.  Preoperativeeywords:
isseminated intravascular coagulation
latelet transfusion
peration
therapy  consisted  of platelet  transfusions  only,  and  intraoperative  hemostasis  was  achieved.  Postopera-
tively,  high-dose  intravenous  immunoglobulin  (IVIg)  therapy  led to an  increased,  stable,  and  adequate
platelet  count  and  good  hemostasis.
DISCUSSION: The  outcome  of  this  case  suggests  that IVIg  therapy  is not  always  required  for preoperative
management  of patients  with.
CONCLUSION: IVIg therapy  may  be useful  for postoperative  management  after  emergency  surgery.
013 T© 2
. Introduction
Idiopathic thrombocytopenic purpura (ITP) is characterized by
 low platelet count that is the result of both immune-mediated
latelet destruction and suppression of platelet production.1,2 In
atients with ITP undergoing surgery, bleeding associated with a
ow preoperative platelet count can lead to unsuccessful outcome.
hen the preoperative platelet count is less than 5 × 104/mm3,
ntensive perioperative management should be planned to avoid
latelet depletion.3,4 Since Imbach and colleagues reported its suc-
essful implementation of high-dose intravenous immunoglobulin
IVIg) therapy in children with ITP, high-dose IVIg therapy has been
Abbreviations: ITP, idiopathic thrombocytopenic purpura; IVIg, intravenous
mmunoglobulin; WBC, white blood cell; CT, computed tomography; CRP, c-reactive
rotein; PT/INR, prothrombin time/international normalized ration; FDP, ﬁbrin
egradation products; DIC, disseminated intravascular coagulation.
∗ Corresponding author at: Department of General Surgical Science (Surgery I),
unma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi,
unma  371-8511, Japan. Tel.: +81 27 220 8224; fax: +81 27 220 8230.
E-mail address: toyomasu@med.gunma-u.ac.jp (Y. Toyomasu).
210-2612 © 2013 The Authors. Published by Elsevier Ltd on behalf of Surgical Associate
ttp://dx.doi.org/10.1016/j.ijscr.2013.05.019he Authors. Published by Elsevier Ltd on behalf of Surgical Associates Ltd. 
recognized to be very effective for the management of acute bleed-
ing during surgery in which blood loss is anticipated.5
However, although intensive medical treatment using IVIg has
been preoperatively administered to patients with low platelet
counts, platelet counts have not increased to satisfactory levels
in some patients.3 Moreover, some studies have found that emer-
gency surgery for patients with less than 5 × 104/mm3 platelets was
successful without the administration of preoperative IVIg.6–8
Here, we  report on a patient with thrombocytopenia due to ITP
who underwent surgery for appendicitis without receiving preop-
erative IVIg therapy. The positive outcome of this case suggests that
preoperative IVIg therapy is not always required for management
of surgical treatment in patients with ITP.
2. Presentation of case
A  66-year-old woman  was brought to the emergency room
of Nakatsu Municipal Hospital because of right lower abdomi-
nal pain. Six months previously, she had been diagnosed with
acute appendicitis and treated by antibiotics. Her signiﬁcant
Open access under CC BY-NC-ND license.past history included ITP that was being treated over the past 4
years with 10 mg  of oral adenocorticoids, and her platelet count
was maintained at around 15 × 104/mm3. Her family history
was unremarkable. In the emergency room, her white blood
s Ltd. Open access under CC BY-NC-ND license.
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oig. 1. Abdominal computed tomography revealed a swollen appendix, and the
urrounding fat tissue showed increased density.
ell (WBC) count was 13,300/mm3 (Neutro: 88.5%), C-reactive
rotein (CRP) was 3.3, and platelet count was  2.3 × 104/mm3.
bdominal computed tomography (CT) revealed a mass arising
rom the appendix and localized abscess formation (Fig. 1). She
as admitted to the hospital with the diagnosis of relapsed
ppendicitis, and broad-spectrum antibiotic coverage was begun.
he next day her temperature increased to 38 ◦C and her WBC
ount to 27,300/mm3 (Neutro: 91.3%), CRP to 8.3, and the platelet
ount decreased to 0.4 × 104/mm3 (Fig. 2). The prothrombin
ime/international normalized ration (PT/INR) decreased to 1.46,
he ﬁbrin degradation products (FDP) increased to 6.1 g/mL, and
he ﬁbrinogen was 353 mg/dL. Because her thrombocytopenia was
hought to be a result of severe ITP or disseminated intravascular
oagulation (DIC) associated with severe appendicitis, surgery was
lanned to take place before IVIg treatment. The patient received
0 units of platelet concentrates before surgery and an additional
0 units of platelet concentrates 1 h after surgical procedure was
egun, to avoid problems with anesthesia and prevent excessive
lood loss. The appendectomy was performed with a blood loss
olume of 248 mL  and without placement of a drainage tube. Fig. 3
hows the swollen appendix and abscess. On the ﬁrst postop-
rative day, the patient’s WBC  decreased, and the platelet count
lso decreased to 0.2 × 104/mm3. The PT-INR increased to 1.64,
he FDP increased to 14.5 g/ml, and ﬁbrinogen was 237 mg/dl.
VIg treatment (20 g/day for 5 days) plus platelet transfusions
ere begun to treat the patient’s ITP, and gabexate mesylate
lus plasma transfusions were administered for her DIC. The
ollowing day, the platelet count increased to 2.7 × 104/mm3
ig. 2. Platelet counts during the clinical course. Immunoglobulin therapy was
dministered on the ﬁrst postoperative day. The platelet count then gradually
ncreased, and a maximum count (19.7 × 104/mm3) was seen on the eighth post-
perative day.Fig. 3. Macroscopic view of the resected swollen appendix. An abscess can be seen.
and her coagulation parameters improved. On the third
postoperative day, her platelet count was 7.2 × 104/mm3 and
the coagulation factors had returned to normal levels. The patient
subsequently made uneventful recovery and was  discharged on
the 14 days after her operation.
3. Discussion
Perioperative bleeding in patients with low platelet counts is
a major risk for patients and an important surgical challenge. The
mean platelet volume of ITP patients increases as the platelet count
decreases, and the larger platelets are assumed to be younger and
more reactive.9–11 Therefore, the bleeding time of ITP patients is
usually shorter than expected for the degree of thrombocytopenia,
and the severity of bleeding in ITP patients is less than that seen
with comparable degrees of thrombocytopenia in bone marrow
failure.12 Several methods have been proposed to elevate the pre-
operative platelet count to the “safe” level. The survival time of
transfused platelets is short, but the increase in platelet count can
be expected to last for around 1 week following immunoglobulin
infusion.13 Therefore, IVIg is an important agent for preopera-
tive management of a planned surgical procedure. However, this
treatment is not always effective, and a signiﬁcant increase in the
platelet count is usually not achieved until 2–3 days following initi-
ation of treatment.5,14 Also, we can administer IVIg as postoperative
therapy instead of preoperative therapy. Considering the possibility
of its side effects (an allergic response, liver dysfunction, and acute
meningitis, etc.), we  choose to administer IVIg not as preoperative,
but as postoperative therapy for our patient. This treatment enabled
us to perform emergency surgery and achieve a good postoperative
course.
Although the duration of hemostatic levels following transfu-
sion is not long enough to be beneﬁcial to ITP patients because of
rapid destruction of the transfused platelets, an immediate increase
in the platelet count can be achieved. A rapid increase in platelet
count is important for emergency surgical operations. Some studies
have demonstrated that platelet transfusions can allow successful
emergency surgeries for patients with ITP without the administra-
tion of preoperative IVIg.6–8
In the normal patient, transfusion of a single platelet concentrate
would be expected to increase the platelet count to approximately
7000–11,000/mm3/m2 body surface area, with a platelet half-life of
about 4 days.15–18 Although platelet survival is shortened in ITP as a
result of platelet destruction, Harker et al. found identical recovery
values in patients with ITP; however, platelet survival as deter-
mined by peripheral platelet count, was reduced to 48–230 min.19Baldini et al. concluded that there are only 2 major indications
for platelet transfusions in patients with ITP: (1) temporary arrest
of an acute life-threatening hemorrhage, or (2) as preparation for
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urgery.20 He recommended transfusing platelet concentrations
–2 h before performing surgery.
Our patient received 10 platelet concentrates before surgery
nd 10 additional platelet concentrates 1 h after the procedure had
egun. With this protocol, we were able to control bleeding during
urgery.
No cases of appendicitis associated with ITP have previously
een reported. We  believe that the association of appendicitis and
TP was incidental in this case.
. Conclusion
We  have reported a patient with thrombocytopenia due to ITP
ho had underwent emergency surgery for appendicitis without
eceiving preoperative IVIg therapy. We  believe that platelet trans-
usions are necessary for preoperative management of emergency
urgical treatment for patients with thrombocytopenia, and that
VIg therapy is not always required for preoperative management.
VIg therapy seems to be suitable for postoperative management of
mergency surgery in patients with ITP.
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